Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial - Wikidata - awgldk - TriplyDB

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial

http://www.wikidata.org/entity/Q35809136

about

Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies Racial/ethnic differences in breast cancer survival by inflammatory status and hormonal receptor status: an analysis of the Surveillance, Epidemiology, and End Results data.Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER.Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.Mortality risk of black women and white women with invasive breast cancer by hormone receptors, HER2, and p53 status Aggressive estrogen-receptor-positive breast cancer arising in patients with elevated body mass index.Ethnic and geographic variations in corpus uteri cancer burden: evidence based on data from 29 states and the District of Columbia. CI5 IX, X and SEER data (1998-2010).Race, response to chemotherapy, and outcome within clinical breast cancer subtypes.Racial and Ethnic Differences in Breast Cancer Survival: Mediating Effect of Tumor Characteristics and Sociodemographic and Treatment Factors Long-Term Follow-Up of the E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in Operable Breast Cancer.Racial differences in outcomes of triple-negative breast cancer Impact of breast cancer subtypes and treatment on survival: an analysis spanning two decades.Her2 positivity and race predict higher mastectomy rates: a SEER database analysis.Patterns and predictors of breast cancer chemotherapy use in Kaiser Permanente Northern California, 2004-2007.African American Race is an Independent Risk Factor in Survival from Initially Diagnosed Localized Breast Cancer.Racial disparities in treatment patterns and clinical outcomes in patients with HER2-positive metastatic breast cancer.Obesity and survival in operable breast cancer patients treated with adjuvant anthracyclines and taxanes according to pathological subtypes: a pooled analysis Engineered dendritic cells for gastrointestinal tumor immunotherapy: opportunities in translational research.Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.Racial disparity in survival from estrogen and progesterone receptor-positive breast cancer: implications for reducing breast cancer mortality disparities.Risk of Recurrence and Mortality in a Multi-Ethnic Breast Cancer Population.Differences in the mutational landscape of triple-negative breast cancer in African Americans and Caucasians.African American patients with breast cancer have worse prognosis than white patients in certain subtypes and stages.Association of race and socioeconomic status and outcomes of patients with rectal cancer.Is the TNM staging system for breast cancer still relevant in the era of biomarkers and emerging personalized medicine for breast cancer - an institution's 10-year experience.Breast cancer survival by molecular subtype: a population-based analysis of cancer registry data.Genomic profiling of breast cancer in African-American women using MammaPrint.The effect of age on race-related breast cancer survival disparities.Estrogen receptor quantitative measures and breast cancer survival.Breast cancer survival, survival disparities, and guideline-based treatment.Prognostic value of breast cancer subtypes, Ki-67 proliferation index, age, and pathologic tumor characteristics on breast cancer survival in Caucasian women.

P2860

Q27014939-2E65DEBF-65BB-4796-B970-6E985E56D1F9 Q30823443-34F2EEBF-6DAA-4DAF-AD4F-C467508B19E1 Q33682910-7CDF695C-97B1-4CF2-9DED-7D6C4131F41B Q33862786-C77F2F26-3176-48E5-9345-4CF285D34D7D Q34705321-3DE4206D-E626-4029-AFD5-B0080FA98B82 Q35186057-5246A00A-53D8-4CC9-9548-94FC4CB5C6A6 Q35200540-8EE159AC-CB45-4527-B4CE-265D031C7FD4 Q35568229-F65C83EA-ABAF-4ECF-A6F6-8B237F8B9AB3 Q35801283-8A6071EE-E30B-4ECD-845F-AC80E36D4B33 Q35847450-7DAA3DAC-8D49-46FE-A342-A77A03FEE7B0 Q35956986-ABE9685A-0B50-48F7-8388-00C28D1375AE Q36306315-18A670B0-074D-4516-A45B-814F90787E6A Q36308052-3E72BE07-DCAD-4A3F-9E1F-14A10E9CD76F Q37161492-9B87F19D-5492-48D3-B725-67C3A4E61137 Q37290523-F2AB80E5-CE75-4DF9-B854-1B5AD57A1C2E Q37298732-6D2BA690-E929-4E7B-B880-3553FA655733 Q37690278-16916644-8F8F-45D5-B689-9E6486AC895B Q38051671-452DEC51-6379-4430-BABC-FDCD65A7F1FF Q38209628-4524F570-A515-4F00-9DF0-45A766871F4B Q38934402-FC524B11-936D-4807-8FB6-04781397E79B Q39076044-54901C6D-D3C0-460C-AE56-7D384CCC0B53 Q39132868-7BD93FE2-3A5F-4038-81D3-61B9B3329599 Q40063848-DF49A322-6DC2-4C89-A317-B69E23A8F17C Q40086705-DD8453E1-B06D-42C0-BFDA-67F9D4531BD7 Q41562136-B7E37D5E-21B4-49CA-98E8-A9997A465887 Q42367695-BE11568A-E8EE-4389-885D-ACFB6752E7A7 Q42498238-E5953ED8-0230-41F0-BC97-DBCCC4DE39A0 Q43463570-3073D3B6-9336-4092-AE79-94C5FDE52BA9 Q47928157-CBAFFBCA-EB1B-4FDD-98C4-1288D8009FFB Q52641223-68F871C3-EBEE-4ECA-9723-503E891E0BCA Q53119241-C27AA536-820B-428C-A099-6D76DD9A96C7

P2860

Race and hormone receptor-positive breast cancer outcomes in a randomized chemotherapy trial

http://www.wikidata.org/entity/Q35809136

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Race and hormone receptor-posi ...... randomized chemotherapy trial

@ast

Race and hormone receptor-posi ...... randomized chemotherapy trial

@en

type

label

Race and hormone receptor-posi ...... randomized chemotherapy trial

@ast

Race and hormone receptor-posi ...... randomized chemotherapy trial

@en

prefLabel

Race and hormone receptor-posi ...... randomized chemotherapy trial

@ast

Race and hormone receptor-posi ...... randomized chemotherapy trial

@en

P1433

Q35809136-6CC66411-F683-4526-8144-C897602771FF

P1476

Q35809136-C622C53C-AF7F-41B8-8948-8E7D72707AC4

P2093

Q35809136-0BCA6447-35C3-498B-9E12-78BBF12E5ADE

Q35809136-3D700398-A98A-42FD-8BCF-4C35BC48CDAC

Q35809136-5162ECB5-8BA0-4883-AB72-133EA724B665

Q35809136-61B74A66-F5CD-4A63-AFE0-1272181B08A5

Q35809136-6C326823-1571-4CCC-BE11-5627C02D02DA

Q35809136-767B0F9B-DD2F-409E-8713-46F26CAC8185

Q35809136-8393A2F7-63F5-45F1-A39A-B6616C74B906

Q35809136-98FBDD67-EB90-4080-94AF-D5BAB51A79CD

Q35809136-C1AF260E-F439-4B04-BCF1-61C4C7253505

Q35809136-E1F091DA-C258-44A0-B2B2-BA3042E1C9EE

P2860

Q35809136-162FEC71-A591-4D7A-969B-D8C3353B0816

Q35809136-24454DA9-44FD-440C-AC24-B722EC3FEFF1

Q35809136-28014D92-18FF-4B1F-B41D-F1E3CA9505E8

Q35809136-323B04DB-E734-45EC-A91D-949AAF68AF4C

Q35809136-38374B84-2FB6-416D-BAD8-DA5EA1820894

Q35809136-448B989E-3C39-47EF-A7D1-A4BDF7C4FF92

Q35809136-518426AD-6CFD-4820-BB9D-E78B00826F1E

Q35809136-5FADE15F-05B5-40D0-8333-1883CC082881

Q35809136-7DD57A9F-D946-4286-8E00-2A9F67CDAC4C

Q35809136-935A1440-D79A-4AF3-83CE-CF3B8DE5422F

P304

Q35809136-35549B9F-7DAC-4180-8329-0D0201F1D636

P31

Q35809136-AFCC4607-CA31-4687-9C2F-1F5B3C26EA0C

P356

Q35809136-365FFC11-4D6A-4778-96B3-FB431FA212B7

P407

Q35809136-687D85D3-C8D6-49CE-9E11-8E7A9199DD3C

P433

Q35809136-D98EB954-DF84-4AAA-A4D5-391B305CE89C

P478

Q35809136-11C33BA1-192A-44C1-84B4-FE27B79D95BC

P50

Q35809136-5BA57D12-EBC0-4D27-998D-4A8E1A06DBB0

P577

Q35809136-D5690F20-BDB3-4BF6-B464-13680ADFE9E6

P5875

Q35809136-D79002DF-3041-4760-A1A8-EAC4A40D735C

P698

Q35809136-913628AA-6B1D-413D-8984-2B59511D8023

P921

Q35809136-86888F13-2C3C-4A1C-A905-95389DB14CC8

P932

Q35809136-434D3AAE-E140-482C-8873-09DB16DDC29E

P356

P1433

Journal of the National Cancer Institute

P1476

Race and hormone receptor-posi ...... randomized chemotherapy trial

@en

P2093

Antonio C Wolff

http://www.w3.org/2001/XMLSchema#string

Edith A Perez

http://www.w3.org/2001/XMLSchema#string

Fengmin Zhao

http://www.w3.org/2001/XMLSchema#string

George W Sledge

http://www.w3.org/2001/XMLSchema#string

Jennifer A Ligibel

http://www.w3.org/2001/XMLSchema#string

Joseph A Sparano

http://www.w3.org/2001/XMLSchema#string

Molin Wang

http://www.w3.org/2001/XMLSchema#string

Nancy E Davidson

http://www.w3.org/2001/XMLSchema#string

Silvana Martino

http://www.w3.org/2001/XMLSchema#string

Tom Saphner

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2009

Supervised risk predictor of breast cancer based on intrinsic subtypes

Survival of blacks and whites after a cancer diagnosis.

Racial and ethnic disparities in the receipt of cancer treatment.

Cross-talk among estrogen receptor, epidermal growth factor, and insulin-like growth factor signaling in breast cancer.

Racial disparities in cancer survival among randomized clinical trials patients of the Southwest Oncology Group.

Obesity and survival among black women and white women 35 to 64 years of age at diagnosis with invasive breast cancer

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

Breast cancer in African-American women.

Treatment quality and outcomes of African American versus white breast cancer patients: retrospective analysis of Southwest Oncology studies S8814/S8897

P304

406-414

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/JNCI/DJR543

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

104

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221752265

http://www.w3.org/2001/XMLSchema#string

P698

22250182

http://www.w3.org/2001/XMLSchema#string

P921

P932

3295746

http://www.w3.org/2001/XMLSchema#string